血清胶质纤维酸性蛋白与神经丝轻链作为多发性硬化疾病进展生物标志物的比较
该研究基于瑞士多发性硬化队列(SMSC)的355例患者和259例健康对照,纵向及横断面检测血清胶质纤维酸性蛋白(sGFAP)和血清神经丝轻链(sNfL)。结果显示sGFAP与疾病进展相关,而sNfL在调整sGFAP后关联消失,两者联合升高可预测确认的残疾恶化。
要点
- sGFAP在女性中比男性高14.9%,随年龄每年增加1.5%,与BMI呈负相关(每BMI单位-1.1%)。
- 在队列1中,进展型MS患者sGFAP较稳定型高50.9%,而sNfL的25%升高在调整sGFAP后消失。
- 在队列2中,sGFAP z评分在将来确认残疾恶化的患者中更高(1.94 vs 0.71),sNfL无显著差异。
核心结论
- sGFAP是未来PIRA的预后生物标志物,与sNfL具有互补潜力。
- sGFAP可能作为MS疾病进展的生物标志物用于个体患者管理和药物开发。
研究设计与样本
- 研究数据来自瑞士MS队列(SMSC),为前瞻性多中心研究,在瑞士8个中心进行,时间范围为2012年1月1日至2022年10月20日。
- 共纳入355例患者(队列1:103例[29.0%],中位年龄42.1岁,女性73例[70.9%];队列2:252例[71.0%],中位年龄44.3岁,女性156例[61.9%])和259例健康对照(中位年龄44.3岁,女性177例[68.3%])。
- 队列1为稳定或恶化残疾且基线EDSS相似、随访期间无复发的MS患者;队列2为所有启动并持续B细胞耗竭治疗(即奥瑞利珠单抗或利妥昔单抗)的SMSC患者。
- 队列1纵向检测sGFAP和sNfL(Simoa法),以健康对照样本为参考;队列2横断面检测sGFAP和sNfL。
主要发现
- 对照中sGFAP随年龄每年增加1.5%(P < .001),与BMI呈负相关(每BMI单位-1.1%;P = .01),女性比男性高14.9%(P = .004)。
- 队列1中,恶化进展型MS患者较稳定MS患者sGFAP高50.9%(额外调整sNfL后),而sNfL的25%升高在额外调整sGFAP后消失。
- 基线sGFAP较高与灰质脑体积损失加速相关(每倍增每年0.24%;P < .001),与白质损失无关。
- sGFAP水平在疾病加重期与缓解期相比保持不变。
- 队列2中,将来确认残疾恶化的患者sGFAP z评分中位数(IQR)为1.94(0.36-2.23),稳定残疾者为0.71(-0.13至1.73)(P = .002);sNfL无显著差异。
临床怎么用
- 作者认为sGFAP可能作为MS疾病进展的生物标志物用于个体患者管理和药物开发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS). OBJECTIVE: To determine how serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) correlate with features of disease progression vs acute focal inflammation in MS and how they can prognosticate disease progression. DESIGN, SETTING, AND PARTICIPANTS: Data were acquired in the longitudinal Swiss MS cohort (SMSC; a consortium of tertiary referral hospitals) from January 1, 2012, to October 20, 2022. The SMSC is a prospective, multicenter study performed in 8 centers in Switzerland. For this nested study, participants had to meet the following inclusion criteria: cohort 1, patients with MS and either stable or worsening disability and similar baseline Expanded Disability Status Scale scores with no relapses during the entire follow-up; and cohort 2, all SMSC study patients who had initiated and continued B-cell-depleting treatment (ie, ocrelizumab or rituximab). EXPOSURES: Patients received standard immunotherapies or were untreated. MAIN OUTCOMES AND MEASURES: In cohort 1, sGFAP and sNfL levels were measured longitudinally using Simoa assays. Healthy control samples served as the reference. In cohort 2, sGFAP and sNfL levels were determined cross-sectionally. RESULTS: This study included a total of 355 patients (103 [29.0%] in cohort 1: median [IQR] age, 42.1 [33.2-47.6] years; 73 female patients [70.9%]; and 252 [71.0%] in cohort 2: median [IQR] age, 44.3 [33.3-54.7] years; 156 female patients [61.9%]) and 259 healthy controls with a median [IQR] age of 44.3 [36.3-52.3] years and 177 female individuals (68.3%). sGFAP levels in controls increased as a function of age (1.5% per year; P < .001), were inversely correlated with BMI (-1.1% per BMI unit; P = .01), and were 14.9% higher in women than in men (P = .004). In cohort 1, patients with worsening progressive MS showed 50.9% higher sGFAP levels compared with those with stable MS after additional sNfL adjustment, whereas the 25% increase of sNfL disappeared after additional sGFAP adjustment. Higher sGFAP at baseline was associated with accelerated gray matter brain volume loss (per doubling: 0.24% per year; P < .001) but not white matter loss. sGFAP levels remained unchanged during disease exacerbations vs remission phases. In cohort 2, median (IQR) sGFAP z scores were higher in patients developing future confirmed disability worsening compared with those with stable disability (1.94 [0.36-2.23] vs 0.71 [-0.13 to 1.73]; P = .002); this was not significant for sNfL. However, the combined elevation of z scores of both biomarkers resulted in a 4- to 5-fold increased risk of confirmed disability worsening (hazard ratio [HR], 4.09; 95% CI, 2.04-8.18; P < .001) and PIRA (HR, 4.71; 95% CI, 2.05-9.77; P < .001). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that sGFAP is a prognostic biomarker for future PIRA and revealed its complementary potential next to sNfL. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.
引用
- Meier S, Willemse EAJ, Schaedelin S, et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023. PMID: 36745446. doi:10.1001/jamaneurol.2022.5250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。